Gilead’s Trodelvy won an FDA nod as a first-line triple-negative breast cancer treatment, with a slightly broader label designed to strengthen its position against other ADCs in the same line of therapy. The expansion gives Trodelvy an advantage in the rapidly evolving competitive landscape for metastatic TNBC, where sequencing and label breadth can determine payer access. The FDA action follows recent momentum from the TNBC drug class, including a wave of approvals and label updates that have pushed companies toward more differentiated companion diagnostic strategies and surveillance models. For Gilead, the next phase will focus on adoption, real-world outcomes, and how clinicians position Trodelvy relative to other first-line options.